CA2841037C - Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease - Google Patents
Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease Download PDFInfo
- Publication number
- CA2841037C CA2841037C CA2841037A CA2841037A CA2841037C CA 2841037 C CA2841037 C CA 2841037C CA 2841037 A CA2841037 A CA 2841037A CA 2841037 A CA2841037 A CA 2841037A CA 2841037 C CA2841037 C CA 2841037C
- Authority
- CA
- Canada
- Prior art keywords
- ethyl
- thiadiazol
- piperazine
- phenyl
- difluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177742.1 | 2011-08-17 | ||
| EP11177742 | 2011-08-17 | ||
| PCT/EP2012/066136 WO2013024168A1 (en) | 2011-08-17 | 2012-08-17 | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2841037A1 CA2841037A1 (en) | 2013-02-21 |
| CA2841037C true CA2841037C (en) | 2020-03-31 |
Family
ID=46826450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2841037A Active CA2841037C (en) | 2011-08-17 | 2012-08-17 | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9187440B2 (https=) |
| EP (1) | EP2744798B1 (https=) |
| JP (1) | JP6051218B2 (https=) |
| CN (1) | CN103649062B (https=) |
| AU (1) | AU2012296804B2 (https=) |
| CA (1) | CA2841037C (https=) |
| ES (1) | ES2573299T3 (https=) |
| PL (1) | PL2744798T3 (https=) |
| WO (1) | WO2013024168A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2744798T3 (pl) * | 2011-08-17 | 2016-08-31 | Remynd Nv | Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera |
| WO2015140130A1 (en) * | 2014-03-17 | 2015-09-24 | Remynd Nv | Oxadiazole compounds |
| WO2025104092A1 (en) * | 2023-11-13 | 2025-05-22 | Remynd N.V. | Modulators of septin 6 for use in the prevention and/or treatment of neurodegenerative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004032567A1 (de) | 2004-07-05 | 2006-03-02 | Grünenthal GmbH | Substituierte 1-Propiolyl-piperazine |
| AU2005324024B2 (en) * | 2005-01-07 | 2011-02-17 | F. Hoffmann-La Roche Ag | [4-(Heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| EP1705474B1 (en) | 2005-03-21 | 2010-04-28 | F.Hoffmann-La Roche Ag | Method for determining lipophilicity |
| PE20070099A1 (es) * | 2005-06-30 | 2007-02-06 | Janssen Pharmaceutica Nv | N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso |
| GB0602335D0 (en) * | 2006-02-07 | 2006-03-15 | Remynd Nv | Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases |
| CA2676715A1 (en) * | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| EP2726470B1 (en) * | 2011-07-01 | 2015-04-29 | reMynd NV | 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases |
| PL2744798T3 (pl) | 2011-08-17 | 2016-08-31 | Remynd Nv | Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera |
-
2012
- 2012-08-17 PL PL12756402T patent/PL2744798T3/pl unknown
- 2012-08-17 ES ES12756402.9T patent/ES2573299T3/es active Active
- 2012-08-17 JP JP2014525462A patent/JP6051218B2/ja not_active Expired - Fee Related
- 2012-08-17 US US14/238,905 patent/US9187440B2/en active Active
- 2012-08-17 CN CN201280034129.3A patent/CN103649062B/zh not_active Expired - Fee Related
- 2012-08-17 EP EP12756402.9A patent/EP2744798B1/en active Active
- 2012-08-17 WO PCT/EP2012/066136 patent/WO2013024168A1/en not_active Ceased
- 2012-08-17 CA CA2841037A patent/CA2841037C/en active Active
- 2012-08-17 AU AU2012296804A patent/AU2012296804B2/en not_active Ceased
-
2015
- 2015-10-15 US US14/884,689 patent/US9808456B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1192848A1 (zh) | 2014-09-05 |
| US20140206699A1 (en) | 2014-07-24 |
| ES2573299T3 (es) | 2016-06-07 |
| US9187440B2 (en) | 2015-11-17 |
| US9808456B2 (en) | 2017-11-07 |
| JP6051218B2 (ja) | 2016-12-27 |
| JP2014521737A (ja) | 2014-08-28 |
| AU2012296804A1 (en) | 2014-01-30 |
| US20160101102A1 (en) | 2016-04-14 |
| WO2013024168A1 (en) | 2013-02-21 |
| CA2841037A1 (en) | 2013-02-21 |
| PL2744798T3 (pl) | 2016-08-31 |
| AU2012296804B2 (en) | 2017-04-20 |
| CN103649062B (zh) | 2015-10-07 |
| CN103649062A (zh) | 2014-03-19 |
| EP2744798B1 (en) | 2016-03-30 |
| EP2744798A1 (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2837247C (en) | 1 , 2 , 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases | |
| US7541359B2 (en) | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | |
| US10538498B2 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| AU2005230392B2 (en) | Thiadiazolidinones as GSK-3 inhibitors | |
| US8093266B2 (en) | Rho kinase inhibitors | |
| AU2005324024B2 (en) | [4-(Heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders | |
| US20110257171A1 (en) | Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors | |
| WO2005042525A1 (en) | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | |
| JP2013544256A (ja) | 複素環式アミンおよびその使用 | |
| JP2009502846A (ja) | Ｇｓｋ−３阻害剤 | |
| CA2841037C (en) | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease | |
| WO2004067000A1 (en) | Benzthiazole-3 oxides useful for the treatment of proliferative disorders | |
| HK1192848B (en) | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease | |
| US20250367209A1 (en) | Identification of novel benzothiazones as tau-sh3 interaction inhibitors for the treatment of alzheimer’s disease | |
| US20050192289A1 (en) | Novel cinnamic amides | |
| HK1192726B (en) | 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170616 |
|
| H11 | Ip right ceased following rejected request for revival |
Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED Effective date: 20250219 |